Flow cytometric immunophenotyping test for staging/monitoring neuroblastoma patients

Wiley - Tập 50 Số 6 - Trang 298-304 - 2002
Michael J. Warzynski1, David M. Graham1, Richard A. Axtell2, James V. Higgins1, Yuki Hammers3
1Department of Pathology and Laboratory Medicine, Spectrum Health, Grand Rapids, Michigan
2Department of Pediatrics, Spectrum Health, Grand Rapids, Michigan
3Department of Pathology and Laboratory Medicine, Children's Hospital Birmingham, Alabama.

Tóm tắt

AbstractTen years ago, we made an incidental flow cytometric observation while immunophenotyping biopsy and marrow samples from children suspected to have leukemia/non‐Hodgkin's lymphoma, but were subsequently diagnosed with neuroblastoma. The samples contained neoplastic CD45− cells that had an extremely bright CD56+ (beyond the fourth decade on a four‐decade scale) population distinguishable from CD45+CD56usual density+ natural killer lymphocytes as well as other CD45−CD56usual density+ nonhematopoietic tumors such as small cell carcinoma or melanoma. Following the “rare event” philosophy of selecting one negative and two positive antigens, we initially tried a “cocktail” of CD45−CD56very bright+ neuron‐specific enolase (NSE)cytoplasmic+. We later modified the procedure to a more clinically applicable “lysed whole blood” CD45−CD56very bright+ ganglioside GD2+ cocktail to improve turnaround time (eliminating the cell permeabilization step for cytoplasmic NSE analysis), specificity, and sensitivity of the assay. A total of 123 marrow/tissue/fluid samples were analyzed by the various forms of the assay. Clearly interpretable samples had an 83% specificity and a 100% sensitivity. The three‐color GD2 assay has successfully detected cells in marrow samples to a level of 0.002% (1 per 105 cells) using patient samples (not artificially “spiked” material). We added CD81 expression of the neuroblastoma cells as a fourth color and now use this rare event clinical test to help stage and monitor all patients with neuroblastoma. Cytometry (Clin. Cytometry) 50:298–304, 2002. © 2002 Wiley‐Liss, Inc.

Từ khóa


Tài liệu tham khảo

Marina NM, 1995, American Cancer Society textbook of clinical oncology, 535

LeeWS ChungWS ChangCD HyunbhBK. Hematopathology no. HP 96‐3 (HP‐13) check sample volume 2 #3. Chicago: American Society of Clinical Pathologists;1996. p33–47.

Kelly DR, 1996, Neoplasia: morphology and biology, 105

Shimada H, 1988, Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age‐linked classification of neuroblastoma, J Clin Oncol, 14, 1874

10.1200/JCO.1988.6.12.1874

10.1007/s100249910047

Warzynski MJ, 2000, Flow cytometry immunophenotyping test for staging/monitoring neuroblastoma patients, Cytometry, 42, 324

Kussick S, 2001, Using antibodies to CD56 and CD45 to identify nonhematopoietic small cell tumors by flow cytometry, Am J Clin Pathol, 116, 279

Shaw S, 1996, Leucocyte typing VI white cell differentiation antigens, 1109

10.1111/j.1600-0609.1994.tb01868.x

10.1016/0005-2760(92)90110-H

Valentine LA, 1990, Neuroblastoma: tumor biology and therapy, 93

10.1200/JCO.1986.4.3.363

Kawashima I, 1990, Monoclonal antibodies to disialogangliosides: characterization of antibody‐mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro, J Biochem, 108, 109, 10.1093/oxfordjournals.jbchem.a123148

10.1007/s002620050008

Cheung NV, 1985, Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells, Cancer Res, 45, 2642

Wu Z, 1986, Expression of GD2 ganglioside by untreated primary human neuroblastomas, Cancer Research, 46, 440

10.1200/JCO.2000.18.24.4067

10.1136/jcp.42.4.422

10.1056/NEJM199101243240403

10.1038/sj.bmt.1700932

10.1097/00043426-200001000-00004

10.1002/(SICI)1097-0142(19980201)82:3<591::AID-CNCR23>3.0.CO;2-W

10.1002/1097-0142(19950601)75:11<2757::AID-CNCR2820751120>3.0.CO;2-S

10.1016/0277-5379(91)90184-F

Mattano LA, 1992, Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase‐polymerase chain reaction, Cancer Res, 52, 4701

Reynolds CP, 1985, Advances in neuroblastoma research, 425

10.1097/00043426-199408000-00003

Sugimot T, 1984, Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia lymphoma cell lines by a panel of 38 monoclonal antibodies, J Natl Cancer Inst, 73, 51

10.1038/bjc.1986.231

Donner L, 1985, Advances in neuroblastoma research, 347

10.1002/1097-0142(19930101)71:1<237::AID-CNCR2820710137>3.0.CO;2-J

10.1128/MCB.10.8.4007

Thông tin
Thông tin xuất bản

Wiley

Tập 50 Số 6

298-304

Thông tin tác giả